Barcelona (Spain), November 17, 2026. We are currently participating in RASEN26 in Sevilla (Barceló Convention Center), a benchmark event for the advancement of neurology and clinical innovation. Throughout the congress, our team is welcoming attendees at our booth located in the Polo Tecnológico to showcase the capabilities of the MAP-AD® test.

MAP-AD® is a CE-IVDR marked prognostic blood tool designed to predict the progression from Mild Cognitive Impairment (MCI) to Alzheimer’s dementia. By integrating the analysis of novel mitochondrial epigenetic biomarkers with patient clinical data using a machine-learning approach, this test allows clinicians to anticipate the evolution of the disease and supports early medical decision-making.

Pitch Session at the Ágora

In addition to our exhibition space, we are part of the official presentation program. We invite you to join our session at the Ágora del Polo Tecnológico to delve into the clinical impact of our technology and its value proposition.

Booth: Polo Tecnológico

Pitch Session: November 18, 2026, 18:00 h | Ágora del Polo Tecnológico